NDLI: Secukinumab: A Silver Lining in Dermatology

Please wait, while we are loading the content...

Secukinumab: A Silver Lining in Dermatology

Content Provider	SAGE Publishing
Author	Manoharan, Dhanaraj Ravi Vignesh, N. Shreya, Srinivasan Saravanan Suzsmi, L.
Copyright Year	2022
Abstract	Secukinumab, a fully human monoclonal antibody, is a biological agent that targets interleukin-17A. Secukinumab is used in the management of the common dermatological entity - plaque-type psoriasis and its various types, namely psoriatic arthritis, hypertrophic palmoplantar psoriasis and generalized pustular psoriasis. Other less common indications of this popular interleukin -17A inhibitor, secukinumab include ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, Familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). This review article was written by referring to various review articles, original articles, and some books related to highly regarded databases, such as the Web of Science, PubMed, and Scopus. The keywords explored during review of literature consisted of combinations of the following words: human monoclonal antibody, IL-17A, and biologicals. The authors with this in-depth review hope to explore the working of this versatile biological, Secukinumab, especially as a silver lining in dermatology.
Related Links	https://journals.sagepub.com/doi/pdf/10.1177/0976500X221105921?download=true
Starting Page	119
Ending Page	124
Page Count	6
ISSN	0976500X
Issue Number	2
Volume Number	13
Journal	Journal of Pharmacology and Pharmacotherapeutics (PHA)
e-ISSN	09765018
DOI	10.1177/0976500X221105921
Language	English
Publisher	Sage Publications India
Publisher Date	2022-07-04
Publisher Place	New Delhi
Access Restriction	Open
Rights Holder	© 2022 Phcog.Net
Rights License	Llicensed Under Creative Commons Licenses
Subject Keyword	Biologicals Secukinumab IL-17A inhibitor Human monoclonal antibody Psoriatic arthritis Psoriasis
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

A Review of the Use of Secukinumab for Psoriatic Arthritis

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

Dual inhibition of IL-17A and IL-17F in psoriatic disease

Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Secukinumab: A Silver Lining in Dermatology

Similar Documents

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

A Review of the Use of Secukinumab for Psoriatic Arthritis

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

Dual inhibition of IL-17A and IL-17F in psoriatic disease

Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

Secukinumab: A Silver Lining in Dermatology